The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Short‐Term, Randomized, Double‐Blind, Parallel‐Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study
Abstract
Dronedarone versus Amiodarone in Patients with AF. Introduction: We compared the efficacy and safety of amiodarone and dronedarone in patients with persistent atrial fibrillation (AF). Methods: Five hundred and four amiodarone‐naïve patients were randomized to receive dronedarone 400 mg bid (n = 249) or amiodarone 600 mg qd for 28 days then 200 mg qd (n = 255) for at least 6 months. Primary composite endpoint was recurrence of AF (including unsuccessful electrical cardioversion, no spontaneous conversion and no electrical cardioversion) or premature study discontinuation. Main safety endpoint (MSE) was occurrence of thyroid‐, hepatic‐, pulmonary‐, neurologic‐, skin‐, eye‐, or gastrointestinal‐specific events, or premature study drug discontinuation following an adverse event. Results: Median treatment duration was 7 months. The primary composite endpoint was 75.1 and 58.8% with dronedarone and amiodarone, respectively, at 12 months (hazard ratio [HR] 1.59; 95% confidence interval [CI] 1.28–1.98; P < 0.0001), mainly driven by AF recurrence with dronedarone compared with amiodarone (63.5 vs 42.0%). AF recurrence after successful cardioversion was 36.5 and 24.3% with dronedarone and amiodarone, respectively. Premature drug discontinuation tended to be less frequent with dronedarone (10.4 vs 13.3%). MSE was 39.3 and 44.5% with dronedarone and amiodarone, respectively, at 12 months (HR = 0.80; 95% CI 0.60–1.07; P = 0.129), and mainly driven by fewer thyroid, neurologic, skin, and ocular events in the dronedarone group. Conclusion: In this short‐term study, dronedarone was less effective than amiodarone in decreasing AF recurrence, but had a better safety profile, specifically with regard to thyroid and neurologic events and a lack of interaction with oral anticoagulants. (J Cardiovasc Electrophysiol, Vol. 21, pp. 597‐605, June 2010)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study
Benjamin, E. J., Wolf, P. A., D’Agostino, R. B., Silbershatz, H., Kannel, W. B., & Levy, D. (1998) · Circulation · doi:10.1161/01.cir.98.10.946 · Cited by 4,575
(2001) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2001.tb01222.x · Cited by 3,461
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
Amiodarone to Prevent Recurrence of Atrial Fibrillation
Roy, D., Talajic, M., Dorian, P., Connolly, S., Eisenberg, M. J., Green, M., Kus, T., Lambert, J., Dubuc, M., Gagné, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421302 · Cited by 1,143
Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
Hohnloser, S. H., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., & Connolly, S. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803778 · Cited by 1,129
Increased Mortality after Dronedarone Therapy for Severe Heart Failure
Køber, L., Torp-Pedersen, C., McMurray, J. J. V., Gøtzsche, O., Lévy, S., Crijns, H., Amlie, J., & Carlsen, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800456 · Cited by 972
Amiodarone versus sotalol for atrial fibrillation
Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041705 · Cited by 749
Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter
Singh, B. N., Connolly, S. J., Crijns, H. J. G. M., Roy, D., Kowey, P. R., Capucci, A., Radzik, D., Aliot, E. M., & Hohnloser, S. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054686 · Cited by 631
Self-citationPrescribing Amiodarone: An Evidence-Based Review of Clinical Indications
Vassallo, P., & Trohman, R. G. (2007) · JAMA · doi:10.1001/jama.298.11.1312 · Cited by 441
Adverse Effects of Low Dose Amiodarone: A Meta-Analysis
Vorperian, V. R., Havighurst, T. C., Miller, S., & January, C. T. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00220-9 · Cited by 419
Dronedarone for prevention of atrial fibrillation: A dose-ranging study
Touboul, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00321-x · Cited by 315
Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism
Trip, M. D., Wiersinga, W., & Plomp, T. A. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90187-3 · Cited by 267
Connolly, S. J., Crijns, H. J. G. M., Torp-Pedersen, C., van Eickels, M., Gaudin, C., Page, R. L., & Hohnloser, S. H. (2009) · Circulation · doi:10.1161/circulationaha.109.875252 · Cited by 261
Wachtell, K., Hornestam, B., Lehto, M., Slotwiner, D. J., Gerdts, E., Olsen, M. H., Aurup, P., Dahlöf, B., Ibsen, H., Julius, S., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.080 · Cited by 243
Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., Woodward, M., Cooper, M., Harrap, S., Hamet, P., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp055 · Cited by 239
Davy, J.-M., Herold, M., Hoglund, C., Timmermans, A., Alings, A., Radzik, D., & Van Kempen, L. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.06.010 · Cited by 234
Self-citationPiccini, J. P., Berger, J. S., & O'Connor, C. M. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp100 · Cited by 198
Sun, W., Sarma, J. S. M., & Singh, B. N. (1999) · Circulation · doi:10.1161/01.cir.100.22.2276 · Cited by 188
Arima, H., Hart, R. G., Colman, S., Chalmers, J. P., Anderson, C. S., Rodgers, A., Woodward, M., MacMahon, S. W., & Neal, B. C. (2005) · Stroke · doi:10.1161/01.str.0000181115.59173.42 · Cited by 115
Pikto−Pietkiewicz, W. (2009) · PubMed · Cited by 113
Thyroid Function Abnormalities during Amiodarone Therapy for Persistent Atrial Fibrillation
Batcher, E. L., Tang, X. C., Singh, B. N., Singh, S. N., Reda, D. J., & Hershman, J. M. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.04.022 · Cited by 105
Sun, W., Sarma, J. S. M., & Singh, B. N. (2002) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200205000-00008 · Cited by 105
Hohnloser, S. H., Connolly, S. J., Crijns, H. J. G. M., Page, R. L., Seiz, W., & Torp-Petersen, C. (2007) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2007.01016.x · Cited by 86
Doyle, J. F., & Ho, K. M. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.3.234 · Cited by 79
Dronedarone: An Emerging Agent with Rhythm‐ and Rate‐Controlling Effects
Wegener, F., Ehrlich, J. R., & Hohnloser, S. H. (2006) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2006.00583.x · Cited by 74
Bongard, V., Marc, D., Philippe, V., Montastruc, J., & Lapeyre‐Mestre, M. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200607000-00007 · Cited by 45
Dronedarone: A New Treatment for Atrial Fibrillation
LAUGHLIN, J. C., & Kowey, P. R. (2008) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2008.01251.x · Cited by 41
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,864
Self-citation2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citation2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Metadata
- Authors
- LE HEUZEY, J., DE FERRARI, G. M., RADZIK, D., SANTINI, M., ZHU, J., & DAVY, J.
- Venue
- Journal of Cardiovascular Electrophysiology
- Publisher
- Wiley
- Published
- 2010-05-17
- Volume
- 21
- Issue
- 6
- Pages
- 597-605
- ISSN
- 1045-3873 (ISSN-L)
- 1540-8167
- OpenAlex
- W2158416204
- Cited by
- 386
- References
- 30
- FWCI
- 41.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.